Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Study of Hepatectomy Combined with Jianpi Huayu Therapy for Hepatocellular Carcinoma

  • Zhong, Chong (Department of Hepatobilliary Surgery, the First Affiliated Hospital to Traditional Chinese Medicine in Guangzhou) ;
  • Li, Hui-Dong (Department of Hepatobilliary Surgery, the First Affiliated Hospital to Traditional Chinese Medicine in Guangzhou) ;
  • Liu, Dong-Yang (Department of Hepatobilliary Surgery, the First Affiliated Hospital to Traditional Chinese Medicine in Guangzhou) ;
  • Xu, Fa-Bin (Department of Hepatobilliary Surgery, the First Affiliated Hospital to Traditional Chinese Medicine in Guangzhou) ;
  • Wu, Jian (Department of Hepatobilliary Surgery, the First Affiliated Hospital to Traditional Chinese Medicine in Guangzhou) ;
  • Lin, Xue-Mei (Department of Hepatobilliary Surgery, the First Affiliated Hospital to Traditional Chinese Medicine in Guangzhou) ;
  • Guo, Rong-Ping (Department of Hepatobilliary Tumors, Cancer Center, Sun Yat-Sen University)
  • Published : 2014.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Traditional Chinese Medicine (TCM) possesses several advantages for treating patients with hepatocellular carcinoma (HCC). The theory of 'Jianpi Huayu Therapy' rooted from 'Jin Kui Yao Lue'is one of the most important therapies in this respect. This study was conducted to investigate the clinical effect and safety of hepatectomy combining with 'Jianpi Huayu Therapy' in the treatment of HCC. Materials and Methods: One hundred and twenty patients with HCC were randomized allocated into hepatectomy combined with 'Jianpi Huayu Therapy' group (treatment group, n=60) and hepatectomy alone group (control group, n=60). Disease- free survival (DFS) and overall survival (OS) were the primary end-points. Liver function at the end of one week after surgery, complications, average days of hospitalization as well as performance status (PS) at the end of one month post operation were also compared. Results: No significant differences existed between two groups on baseline analysis (p>0.05). No treatment related mortality occurred in either group. Post-operative complications were detected among 14 patients (23.3%) in the treatment group, and 12 (20.0%) in the control group (p=0.658). Alanine aminotransferase (ALT) at the end of one week after operation was lower in the treatment than control groups (p=0.042). No significant differences in other indexes of liver function were discovered between two groups. Average days of hospitalization reduced by 0.9 day in treatment group than in control (p=0.034). During follow-up, 104 patients (86.6%) developed recurrence. The rates of 1-, 3-, and 5-year DFS and median DFS for all patients were 77.4%, 26.3%, 9.0% and 25.6 months (range, 6.0~68.0), respectively (78.2%, 29.2%, 14.3% and 28.7 months for the 48 patients in the treatment group and 75.0%, 23.3%, 6.4%, and 22.6 months for the 56 patients in the control group (p=0.045)). 101 patients had died at the time of censor, with 1-, 3-, and 5-year overall survival rates and median survival for all patients of 97.5%, 76.4%, 40.5% and 51.2 months (range, 10.0~72.0), respectively (98.3%, 78.0%, 43.6% and 52.6 months, for treatment and 96.7%, 74.7%, 37.4%, and 49.8 months, for controls, respectively (p=0.048)). Conclusions: Hepatectomy combined with 'Jianpi Huayu therapy'was effective in the treatment of HCC, and reduced post-operative recurrence and metastasis and improved DFS and OS of HCC patients.

Keywords

References

  1. Abdelgawad IA, Mossallam GI, Radwan NH, et al (2013). Can glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev, 14, 7345-9. https://doi.org/10.7314/APJCP.2013.14.12.7345
  2. Ahmad Z, Arshad H, Fatima S, et al (2013). Gastrointestinal, liver and biliary tract pathology: a histopathological and epidemiological perspective from Pakistan with a review of the literature. Asian Pac J Cancer Prev, 14, 6997-7005. https://doi.org/10.7314/APJCP.2013.14.11.6997
  3. Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Asian Pac J Cancer Prev, 14, 7367-9. https://doi.org/10.7314/APJCP.2013.14.12.7367
  4. Banjerdpongchai R, Wudtiwai B, Sringarm K (2013). Cytotoxic and apoptotic-inducing effects of purple rice extracts and chemotherapeutic drugs on human cancer cell lines. Asian Pac J Cancer Prev, 14, 6541-8. https://doi.org/10.7314/APJCP.2013.14.11.6541
  5. Chittmittrapap S, Chieochansin T, Chaiteerakij, et al (2013). Prevalence of aflatoxin induced p53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg). Asian Pac J Cancer Prev, 14, 7675-9. https://doi.org/10.7314/APJCP.2013.14.12.7675
  6. Chen HL, Zhou DH (2003). The experience to treat liver cancer. J Traditional Chinese Med, 44, 894-895.
  7. Caldwell S, Park SH (2009). The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol, 44, 96-101. https://doi.org/10.1007/s00535-008-2258-6
  8. Chen XL, Wang BQ (2007). Introduction to pixu and the correlation of liver cancer. Trad Chin Med Jilin, 27, 5-7.
  9. Cheung F, Wang X, Wang N, et al (2013). Chinese medicines as an adjuvant therapy for unresectable hepatocellular carcinoma during transarterial chemoembolization: a Meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med, 2013, 487919.
  10. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
  11. Guo RP, Zhong C, Shi M, et al (2006). Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol, 132, 547-55. https://doi.org/10.1007/s00432-006-0097-5
  12. Gupta SP, Mittal A, Sathian B, et al (2013). Elevated serum insulin is an independent risk factor for hepatocellular carcinoma: a case control study from Nepal. Asian Pac J Cancer Prev, 14, 7331-3. https://doi.org/10.7314/APJCP.2013.14.12.7331
  13. Gao FY, Li YF, Zhang AQ (2011). Research progress of traditional Chinese medicine in the treatment of primary liver cancer. China Cancer, 20, 764-767.
  14. Hao YX, Wang JP, Zhao LF (2013). Associations between three common MicroRNA polymorphisms and hepatocellular carcinoma risk in Chinese. Asian Pac J Cancer Prev, 14, 6601-4 https://doi.org/10.7314/APJCP.2013.14.11.6601
  15. Hu Y, Chen RS (2008). Treatment of liver cancer experience isintroduced. J New Chinese Med, 40, 12.
  16. Liu XN, Li N (2012). Primary liver cancer clinical medication meta-analysis of traditional Chinese medicine. China J Chin Mater Med, 37, 1327-31.
  17. Li GH, Chen MS, Li JQ, et al (2002). The effect of the resection of liver cancer and experience. Chinese J Hepatobiliary Surgery, 8, 190-1.
  18. Ministry of Health of the People's Republic of China (2011). Primary liver cancer diagnosis and treatment standards (2011 edition), J Clin Oncol, 929-46.
  19. Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9 https://doi.org/10.7314/APJCP.2013.14.11.6955
  20. Shi M, Guo RP, Lin XJ, et al (2007). Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg, 245, 36-43. https://doi.org/10.1097/01.sla.0000231758.07868.71
  21. Sobin LH, Gospodarowicz MK, Wittekind C (2019). International Union Against Cancer (UICC). TNM classification of malignant tumours (7thed)[S]. New York:Wiley-Liss, 80-85.
  22. Su XK, Ye XW, Lin MQ, et al (2006). Method of 'jian pi hua yu '82 cases of postoperative recurrence of liver cancer clinical research. J Traditional Chinese Med, 47, 673-5.
  23. Tang ZY (2011). Combine traditional Chinese and western medicine treatment of liver cancer. Combine traditional Chinese and western medicine liver disease 21, 129-30.
  24. The state food and drug administration. Chinese medicine new medicine clinical research guiding principle (2002). Beijing: China medical science and technology press, kunming, China. 210-2.
  25. Tian YZ, Li HY, Du HT (2012). Combine traditional chinese and western medicine treatment curative effect of liver cancer research. J Chinese Med, 27, 1246-7.
  26. Wu MC, Chen H, Shen F (2001). Surgical treatment of primary liver cancer, with 5524 cases report. Chin J Surg, 39, 25-8.
  27. Yang HL, (2013). The clinical value of w.k.che treated from the spleen liver cancer. J Traditional Chinese Med, 54, 623-4.
  28. Yu RX (2001). Thinking of the TCM therapy for cancer. tumour, 21, 419-20
  29. Ye SL, Qin SK, Wu MC, et al (2009). Experts consensus on diagnosis and treatment for primary hepatocellular carcinoma4.29 (4):295-304.
  30. Zhu WJ, Huang CY, Li C, et al (2013). Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting milan criteria after curative resection. Asian Pac J Cancer Prev, 14, 7101-6. https://doi.org/10.7314/APJCP.2013.14.12.7101
  31. Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, et al (2013). Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev, 14, 6721-6. https://doi.org/10.7314/APJCP.2013.14.11.6721
  32. Zhang J, Wang R, Ma YY, et al (2013). Association between single nucleotide polymorphisms in miRNA196a-2 and miRNA146a and susceptibility to hepatocellular carcinoma in a Chinese population. Asian Pac J Cancer Prev, 14, 6427-31. https://doi.org/10.7314/APJCP.2013.14.11.6427
  33. Zhong C, Guo RP, Li JQ, et al (2009). A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol, 135, 1437-45. https://doi.org/10.1007/s00432-009-0588-2
  34. Zhang XW, Yan XJ, Zhou ZR, et al (2010). Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 328, 240-3. https://doi.org/10.1126/science.1183424
  35. Zhen XT, Lin LZ (2009). Experience in treatment of primary liver cancer is introduced. J New Chin Med, 41, 11-2.
  36. Zhou XD, Tang ZY, Yang BH, et al (2001). Experience in 1000 cases of small liver cancer resection. Chin J Pract Surg, 21, 41-4.

Cited by

  1. Hepatoprotective Effects of Curcumin Against Diethyl Nitrosamine Induced Hepatotoxicity in Albino Rats vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.103
  2. Implications of Sex Hormone Receptor Gene Expression in the Predominance of Hepatocellular Carcinoma in Males: Role of Natural Products vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4949
  3. Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials vol.2017, pp.1741-4288, 2017, https://doi.org/10.1155/2017/3428253
  4. A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China vol.17, pp.3, 2018, https://doi.org/10.1177/1534735418775819